Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Accured Expenses (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Change in Accured Expenses for 10 consecutive years, with -$34000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 107.98% to -$34000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.9 million, a 291.18% decrease, with the full-year FY2024 number at $1.7 million, up 542.67% from a year prior.
  • Change in Accured Expenses was -$34000.0 for Q3 2025 at Rein Therapeutics, up from -$3.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q2 2024 to a low of -$3.2 million in Q2 2025.
  • A 5-year average of -$129578.9 and a median of $79000.0 in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: tumbled 737.61% in 2022, then surged 473.24% in 2023.
  • Rein Therapeutics' Change in Accured Expenses stood at -$226000.0 in 2021, then crashed by 737.61% to -$1.9 million in 2022, then surged by 105.76% to $109000.0 in 2023, then surged by 136.7% to $258000.0 in 2024, then tumbled by 113.18% to -$34000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Change in Accured Expenses are -$34000.0 (Q3 2025), -$3.2 million (Q2 2025), and -$10000.0 (Q1 2025).